184 related articles for article (PubMed ID: 32415711)
21. Tocilizumab in chronic active antibody-mediated rejection: rationale and protocol of an in-progress randomized controlled open-label multi-center trial (INTERCEPT study).
Streichart L; Felldin M; Ekberg J; Mjörnstedt L; Lindnér P; Lennerling A; Bröcker V; Mölne J; Holgersson J; Daenen K; Wennberg L; Lorant T; Baid-Agrawal S
Trials; 2024 Mar; 25(1):213. PubMed ID: 38519988
[TBL] [Abstract][Full Text] [Related]
22. Rabbit anti-human thymocyte immunoglobulin for the rescue treatment of chronic antibody-mediated rejection after pediatric kidney transplantation.
Cihan Y; Kanzelmeyer N; Drube J; Kreuzer M; Lerch C; Hennies I; Froede K; Verboom M; Ahlenstiel-Grunow T; Pape L
Pediatr Nephrol; 2017 Nov; 32(11):2133-2142. PubMed ID: 28717935
[TBL] [Abstract][Full Text] [Related]
23. Six-year outcomes in broadly HLA-sensitized living donor transplant recipients desensitized with intravenous immunoglobulin and rituximab.
Kahwaji J; Jordan SC; Najjar R; Wongsaroj P; Choi J; Peng A; Villicana R; Vo A
Transpl Int; 2016 Dec; 29(12):1276-1285. PubMed ID: 27529314
[TBL] [Abstract][Full Text] [Related]
24. Clinical Outcome of Rituximab and Intravenous Immunoglobulin Combination Therapy in Kidney Transplant Recipients with Chronic Active Antibody-Mediated Rejection.
Ban TH; Yu JH; Chung BH; Choi BS; Park CW; Kim YS; Yang CW
Ann Transplant; 2017 Aug; 22():468-474. PubMed ID: 28775248
[TBL] [Abstract][Full Text] [Related]
25. Comparing transplant glomerulopathy in the absence of C4d deposition and donor-specific antibodies to chronic antibody-mediated rejection.
Torres IB; Salcedo M; Moreso F; Sellarés J; Castellá E; Azancot MA; Perelló M; Cantarell C; Serón D
Clin Transplant; 2014 Oct; 28(10):1148-54. PubMed ID: 25103874
[TBL] [Abstract][Full Text] [Related]
26. Clinical outcome in patients with chronic antibody-mediated rejection treated with and without rituximab and intravenous immunoglobulin combination therapy.
Chung BH; Kim Y; Jeong HS; Hong YA; Choi BS; Park CW; Choi YJ; Kim YS; Yang CW
Transpl Immunol; 2014 Sep; 31(3):140-4. PubMed ID: 25179826
[TBL] [Abstract][Full Text] [Related]
27. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation.
Vo AA; Peng A; Toyoda M; Kahwaji J; Cao K; Lai CH; Reinsmoen NL; Villicana R; Jordan SC
Transplantation; 2010 May; 89(9):1095-102. PubMed ID: 20110854
[TBL] [Abstract][Full Text] [Related]
28. Tocilizumab for treatment of chronic active antibody-mediated rejection in kidney transplant recipients.
Boonpheng B; De Castro ICC; Ng YH; Blosser C; Bakthavatsalam R; Gimferrer I; Smith K; Leca N
Clin Transplant; 2023 May; 37(5):e14936. PubMed ID: 36787372
[TBL] [Abstract][Full Text] [Related]
29. Tocilizumab in the Treatment of Chronic Antibody-Mediated Rejection Post Kidney Transplantation: Clinical and Histological Monitoring.
Noble J; Giovannini D; Laamech R; Imerzoukene F; Janbon B; Marchesi L; Malvezzi P; Jouve T; Rostaing L
Front Med (Lausanne); 2021; 8():790547. PubMed ID: 35004757
[No Abstract] [Full Text] [Related]
30. Lack of Histological and Molecular Signature Response to Tocilizumab in Kidney Transplants with Chronic Active Antibody Mediated Rejection: A Case Series.
Kumar D; Yakubu I; Safavi F; Levy M; Moinuddin I; Kimball P; Kamal L; King A; Massey D; Halloran P; Gupta G
Kidney360; 2020 Jul; 1(7):663-670. PubMed ID: 35372943
[TBL] [Abstract][Full Text] [Related]
31. [Role of antibodies in kidney transplant].
Ruffoni E; Seveso M; Marson P; Tison T; Cozzi E
G Ital Nefrol; 2012; 29 Suppl 54():S54-60. PubMed ID: 22388831
[TBL] [Abstract][Full Text] [Related]
32. Histopathologic features of transplant glomerulopathy associated with response to therapy with intravenous immune globulin and rituximab.
Kahwaji J; Najjar R; Kancherla D; Villicana R; Peng A; Jordan S; Vo A; Haas M
Clin Transplant; 2014 May; 28(5):546-53. PubMed ID: 24579925
[TBL] [Abstract][Full Text] [Related]
33. The efficacy and safety of anti-interleukin-6 receptor monoclonal blockade in a renal transplant patient with Castleman disease: early post-transplant outcome.
Matsunami M; Ubara Y; Sumida K; Oshima Y; Oguro M; Kinoshita K; Tanaka K; Nakamura Y; Kinowaki K; Ohashi K; Fujii T; Igawa T; Sato Y; Ishii Y
BMC Nephrol; 2018 Oct; 19(1):263. PubMed ID: 30314457
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological analysis of transplant glomerulopathy cases.
Shimizu T; Ishida H; Shirakawa H; Omoto K; Tsunoyama K; Iida S; Tanabe K; Yamaguchi Y
Clin Transplant; 2009 Aug; 23 Suppl 20():39-43. PubMed ID: 19594595
[TBL] [Abstract][Full Text] [Related]
35. Successful use of nonantigen-specific immunoadsorption with antihuman Ig-columns in kidney graft antibody-mediated rejection.
Montagud-Marrahi E; Revuelta I; Cucchiari D; Piñeiro GJ; Ventura-Aguiar P; Lozano M; Cid J; Martorell J; Solé M; Quintana LF; Oppenheimer F; Diekmann F; Poch E; Campistol JM; Blasco M
J Clin Apher; 2020 Jun; 35(3):188-199. PubMed ID: 32219886
[TBL] [Abstract][Full Text] [Related]
36. Absence of IL-6 Receptor Blockade Effect on the Outcomes of Transplant Glomerulopathy in the Absence of Anti-HLA Donor-specific Antibodies.
Mella A; Lavacca A; Dodoi DT; Presta R; Fop F; Campagna M; Manzione AM; Dolla C; Gallo E; Abbasciano I; Gai C; Camussi G; Barreca A; Caorsi C; Giovinazzo G; Biancone L
Transplant Direct; 2024 Jun; 10(6):e1638. PubMed ID: 38769985
[TBL] [Abstract][Full Text] [Related]
37. Morphologic patterns and treatment of transplant glomerulopathy: A retrospective analysis.
Abreu R; Carvalho F; Viana H; Mesquita I; Possante M; Aires I; Caeiro F; Silva C; Cotovio P; Ferreira A; Remédio F; Nolasco F
Clin Transplant; 2017 Apr; 31(4):. PubMed ID: 28135784
[TBL] [Abstract][Full Text] [Related]
38. Partial therapeutic response to Rituximab for the treatment of chronic alloantibody mediated rejection of kidney allografts.
Smith RN; Malik F; Goes N; Farris AB; Zorn E; Saidman S; Tolkoff-Rubin N; Puri S; Wong W
Transpl Immunol; 2012 Oct; 27(2-3):107-13. PubMed ID: 22960786
[TBL] [Abstract][Full Text] [Related]
39. Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis.
Gosset C; Viglietti D; Rabant M; Vérine J; Aubert O; Glotz D; Legendre C; Taupin JL; Duong Van-Huyen JP; Loupy A; Lefaucheur C
Kidney Int; 2017 Sep; 92(3):729-742. PubMed ID: 28554738
[TBL] [Abstract][Full Text] [Related]
40. The New Challenge in Pediatric Liver Transplantation: Chronic Antibody-Mediated Rejection.
Uebayashi EY; Okajima H; Yamamoto M; Ogawa E; Okamoto T; Haga H; Hatano E
J Clin Med; 2022 Aug; 11(16):. PubMed ID: 36013073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
